Day: August 13, 2021

TORONTO, Aug. 13, 2021 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced its financial results for the second quarter ended June 30, 2021, and provided a corporate update. “We are pleased to report continued positive progress, both clinically and operationally, throughout the second quarter,” commented, Chris Seto, CEO of Spectral. “Specifically, our Tigris trial is getting back on track following delays due to the pandemic, with recruitment activities returning to normalized levels as well as onboarding of the remaining clinical...

HONG KONG, Aug. 13, 2021 (GLOBE NEWSWIRE) — SouthGobi Resources Ltd. (Toronto Stock Exchange (“TSX”): SGQ, Hong Kong Stock Exchange (“HKEX”): 1878) (the “Company” or “SouthGobi”) today announces its financial and operating results for the three and six months ended June 30, 2021. All figures are in U.S. dollars (“USD”) unless otherwise stated. Significant Events and Highlights The Company’s significant events and highlights for the three months ended June 30, 2021 and the subsequent period up to August 13, 2021 are as follows:Operating Results – In response to the increase in Coronavirus Disease 2019 (“COVID-19”) case numbers in Mongolia in the second quarter of 2021, the Chinese authorities has been restricting the number of trucks permitted to cross the Ceke port of entry, and such restriction has severely impacted...

— Achieves Record Quarterly Revenues — MONTREAL, Aug. 13, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2021. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q2 2021 Highlights FinancialsRevenues were a record $65,796, an increase of $12,546 or 24% over prior year. Gross margin of $28,871 or 44% compared to $22,237 or 42% in prior year. Adjusted EBITDA1 was $9,396, an increase of $1,743 or 23% over prior year. Gain from strategic fund investments of $28,479, of which $4,872 was realized. Net income was $29,004, an increase of $13,492 or 87% over...

Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Company’s DLA portfolio Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacase YONKERS, N.Y., Aug. 13, 2021 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the second quarter ended June 30, 2021. “ContraFect has positively executed on every program in our portfolio. We published several significant manuscripts and presented data that highlights the potential of our DLAs to...

MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2021. “HCW Biologics delivered on a milestone as we achieved our goal of closing our initial public offering on July 22 to raise capital to advance the clinical development of our lead molecules,” stated Hing C. Wong, Ph.D., founder and CEO of HCW Biologics Inc. “We started HCW Biologics three years ago with an idea to develop immunotherapeutic treatments for age-related diseases. Since that time, we applied our expertise...

Strengthened the Company’s balance sheet by completing the business combination with Therapeutics Acquisition Corp (“RACA”), with gross proceeds from the transaction totaling approximately $286.7 million Completion of enrollment of the 25-patient safety and dosimetry lead-in in the Phase 3 SPLASH study to evaluate the efficacy of PNT2002 in patients with mCRPC INDIANAPOLIS, Aug. 13, 2021 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life changing radiopharmaceuticals, today announced financial results for the second quarter ended June 30, 2021 and provided a business update. “During Q2 2021, POINT listed on NASDAQ and now has $273.7 million of cash to transform POINT into a global radioligand leader,” said Dr. Joe McCann,...

TORONTO, Aug. 13, 2021 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2021. Second Quarter 2021 Summary & Recent Highlights:Total revenue of $25.8 million, up $8.8 million, or 52%, year-over-year. Gross margin of 72.5%, up approximately 250 basis points year-over-year. GAAP operating income of $1.5 million, up $10.3 million, or 117%, year-over-year. GAAP net income attributable to stockholders of $0.4 million, up $13.5 million, or 103%, year-over-year. Adjusted EBITDA of $0.5 million, up $3.2 million, or 117%, year-over-year. On July 20, 2021, the Company announced that it received a medical device license issued by Health Canada to market the Venus Fiore Feminine...